{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:19:05Z","timestamp":1777612745947,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin EEG Neurosci"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:p>A drug interaction refers to an event in which the usual pharmacological effect of a drug is modified by other factors, most frequently additional drugs. When two drugs are administered simultaneously, or within a short time of each other, an interaction can occur that may increase or decrease the intended magnitude or duration of the effect of one or both drugs. Drugs may interact on a pharmaceutical, pharmacokinetic or pharmacodynamic basis. Pharmacodynamic interactions arise when the alteration of the effects occurs at the site of action.<\/jats:p>\n                  <jats:p>This is a wide field where not only interactions between different drugs are considered but also drug and metabolites (midazolam\/\u03b1-hydroxy-midazolam), enantiomers (ketamine), as well as phenomena such as tolerance (nor-diazepam) and sensitization (diazepam). Pharmacodynamic interactions can result in antagonism or synergism and can originate at a receptor level (antagonism, partial agonism, down-regulation, up-regulation), at an intraneuronal level (transduction, uptake), or at an interneuronal level (physiological pathways).<\/jats:p>\n                  <jats:p>Alternatively, psychotropic drug interactions assessed through quantitative pharmaco-EEG can be viewed according to the broad underlying objective of the study: safety-oriented (ketoprofen\/theophylline, lorazepam\/-diphenhydramine, granisetron\/haloperidol), strictly pharmacologically-oriented (benzodiazepine receptors), or broadly neuro-physiologically-oriented (diazepam\/buspirone). Methodological issues are stressed, particularly drug plasma concentrations, dose-response relationships and time-course of effects (fluoxetine\/buspirone), and unsolved questions are addressed (yohimbine\/caffeine, hydroxizyne\/alcohol).<\/jats:p>","DOI":"10.1177\/155005940603700208","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T16:03:18Z","timestamp":1329926598000},"page":"108-120","source":"Crossref","is-referenced-by-count":8,"title":["Quantifying Drug-Drug Interactions in Pharmaco-EEG"],"prefix":"10.1177","volume":"37","author":[{"given":"M.J.","family":"Barbanoj","sequence":"first","affiliation":[{"name":"Centre d'Investigaci\u00f3 tie Medicaments, Institut de Recerca; Servei de Farmacologia Cl\u00ednica, Hospital de la Santa Creu i Sant Pau (HSCSP)"},{"name":"Centre de Recerca en Enginyeria Biom\u00e8dica, Departament ESAII, Universitat Polit\u00e8cnica de Catalunya, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Antonijoan","sequence":"additional","affiliation":[{"name":"Centre d'Investigaci\u00f3 tie Medicaments, Institut de Recerca; Servei de Farmacologia Cl\u00ednica, Hospital de la Santa Creu i Sant Pau (HSCSP)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Riba","sequence":"additional","affiliation":[{"name":"Centre d'Investigaci\u00f3 tie Medicaments, Institut de Recerca; Servei de Farmacologia Cl\u00ednica, Hospital de la Santa Creu i Sant Pau (HSCSP)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Valle","sequence":"additional","affiliation":[{"name":"Centre d'Investigaci\u00f3 tie Medicaments, Institut de Recerca; Servei de Farmacologia Cl\u00ednica, Hospital de la Santa Creu i Sant Pau (HSCSP)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Romero","sequence":"additional","affiliation":[{"name":"Centre d'Investigaci\u00f3 tie Medicaments, Institut de Recerca; Servei de Farmacologia Cl\u00ednica, Hospital de la Santa Creu i Sant Pau (HSCSP)"},{"name":"Departament de Farmacologia i Terap\u00e8utica, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Jan\u00e9","sequence":"additional","affiliation":[{"name":"Centre d'Investigaci\u00f3 tie Medicaments, Institut de Recerca; Servei de Farmacologia Cl\u00ednica, Hospital de la Santa Creu i Sant Pau (HSCSP)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"bibr1-155005940603700208","first-page":"181","volume-title":"Human Psychopharmacology","volume":"5","author":"Barbanoj MJ","year":"1995"},{"key":"bibr2-155005940603700208","first-page":"129","volume":"24","author":"Valle M","year":"2002","journal-title":"Meth Find Exp Clin Pharmacol"},{"key":"bibr3-155005940603700208","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199120060-00006"},{"key":"bibr4-155005940603700208","first-page":"36","volume":"260","author":"Mandema JW","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr5-155005940603700208","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223030-00003"},{"key":"bibr6-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.84"},{"key":"bibr7-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1007\/BF01066320"},{"key":"bibr8-155005940603700208","first-page":"114","volume":"20","author":"Barbanoj MJ","year":"1998","journal-title":"Meth Find Exp Clin Pharmacol"},{"key":"bibr9-155005940603700208","first-page":"258","volume":"23","author":"Matejcek M","year":"1985","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"bibr10-155005940603700208","first-page":"909","volume":"44","author":"Saletu B","year":"1998","journal-title":"Curr Ther Res"},{"key":"bibr11-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04109.x"},{"key":"bibr12-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02929.x"},{"key":"bibr13-155005940603700208","unstructured":"Barbanoj MJ, Anderer P, Antonijoan RM, Torrent J, Saletu B, Jan\u00e9 F. Central effects of buspirone and its interaction with diazepam: a pharmaco-EEG brain mapping study. G\u00f6teborg: 6th Biennial IPEG Meeting; 1990. Abstract."},{"key":"bibr14-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000125689.05091.c6"},{"key":"bibr15-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1159\/000085206"},{"key":"bibr16-155005940603700208","first-page":"170","volume":"24","author":"Barbanoj MJ","year":"2002","journal-title":"Meth Find Exp Clin Pharmacol"},{"key":"bibr17-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.106"},{"key":"bibr18-155005940603700208","first-page":"S56","volume":"113","author":"Barbanoj MJ","year":"2002","journal-title":"Clin Neurophysiol"},{"key":"bibr19-155005940603700208","first-page":"51","volume":"24","author":"Barbanoj MJ","year":"2002","journal-title":"Meth Find Exp Clin Pharmacol"},{"key":"bibr20-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1159\/000118963"},{"key":"bibr21-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199510000-00014"},{"key":"bibr22-155005940603700208","volume-title":"Sex or pre-treatment differences on EEG-effects of morfine in low concentrations?. Zurich: 8th World Congress of the International Society for Brain Electromagnetic Topography (ISBET)","author":"Barbanoj MJ","year":"1997"},{"key":"bibr23-155005940603700208","volume-title":"Central effects of buspirone and its interaction with fluoxetine: PK and PD data using topographic pharmaco-EEG mapping. Prague: 9th Biennial IPEG Meeting","author":"Barbanoj MJ","year":"1996"},{"key":"bibr24-155005940603700208","volume-title":"Opposite pharmaco-EEG changes after separate drug intake may result, depending on their topographic distribution, in different patterns when taken simultaneously. Zurich: 7th Swiss Brain Mapping Meeting","author":"Barbanoj MJ","year":"1994"},{"key":"bibr25-155005940603700208","unstructured":"Barbanoj MJ, Anderer P, Garc\u00eda-Gea C, Morte A, Riba J, Antonijoan RM,  Are CNS activity always associated with significant pharmaco-EEG changes? Vienna: 11th Biennial IPEG Meeting; 2000."},{"key":"bibr26-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bioeng.5.040202.121601"},{"key":"bibr27-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1109\/51.956819"},{"key":"bibr28-155005940603700208","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/15.2.95"}],"container-title":["Clinical EEG and Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/155005940603700208","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/155005940603700208","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/155005940603700208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:11:08Z","timestamp":1777403468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/155005940603700208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1177\/155005940603700208"],"URL":"https:\/\/doi.org\/10.1177\/155005940603700208","relation":{},"ISSN":["1550-0594","2169-5202"],"issn-type":[{"value":"1550-0594","type":"print"},{"value":"2169-5202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}